ArticleThe Journal of biological chemistry2011
HoxA10 regulates transcription of the gene encoding transforming growth factor beta2 (TGFbeta2) in myeloid cells.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 43 citations in OpenAlex.
- Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia.The Journal of clinical investigation · 2025Article
- Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- MicroRNA target homeobox messenger RNA in HIV induced hematopoietic inhibition.Frontiers in cell and developmental biology · 2024Article
- Review
- An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.Journal of clinical laboratory analysis · 2022Article
- Molecular implications of HOX genes targeting multiple signaling pathways in cancer.Cell biology and toxicology · 2022Review
- HOXA10 enhances cell proliferation and suppresses apoptosis in esophageal cancer via activating p38/ERK signaling pathway.Open medicine (Warsaw, Poland) · 2022Article
- Mechanosensitive miR-100 coordinates TGFβ and Wnt signaling in osteocytes during fluid shear stress.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Site-Specific Fracture Healing: Comparison between Diaphysis and Metaphysis in the Mouse Long Bone.International journal of molecular sciences · 2021Review
- Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression.Cancers · 2021Review
- HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis.Journal of experimental & clinical cancer research : CR · 2021Article
- Inhibition of post-trabeculectomy fibrosisActa pharmaceutica Sinica. B · 2020Article
- An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse inThe Journal of biological chemistry · 2020Article
- HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway.Cancer management and research · 2019Article
- The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.Oncogene · 2018Article
- Article
- Hoxa10 null animals exhibit reduced platelet biogenesis.British journal of haematology · 2016Article
- HoxA10 Terminates Emergency Granulopoiesis by Increasing Expression of Triad1.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.Cancer research · 2015Article
- HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
HoxA10 is a homeodomain transcription factor that is maximally expressed in myeloid progenitor cells. HoxA10 is overexpressed in a poor prognosis subset of human acute myeloid leukemia (AML) and in vivo overexpression of HoxA10 in murine bone marrow induces myeloid leukemia. HoxA10 contributes to myeloid progenitor expansion and differentiation block, but few target genes have been identified that explain the influence of HoxA10 on these processes. The current study identifies the gene encoding transforming growth factor β2 (TGFβ2) as a HoxA10 target gene. We found that HoxA10 activated TGFβ2 transcription by interacting with tandem cis elements in the promoter. We also determined that HoxA10 overexpression in myeloid progenitor cells increased Tgfβ2 production by the cells. Tgfβ2 stimulates proliferation of hematopoietic stem and progenitor cells. Therefore, these studies identified autocrine stimulation of myeloid progenitors by Tgfβ2 as one mechanism by which HoxA10 expands this population. Because HoxA proteins had not been previously known to influence expression of pro-proliferative cytokines, this has implications for understanding molecular mechanisms involved in progenitor expansion and the pathobiology of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.